Literature DB >> 27050050

Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?

Dan Turner1, Arie Levine, Thomas D Walters, Gili Focht, Anthony Otley, Victor Navas López, Sibylle Koletzko, Robert Baldassano, David Mack, Jeffrey Hyams, Anne M Griffiths.   

Abstract

INTRODUCTION: There is increasing interest in measuring mucosal inflammation in Crohn disease (CD), but there are minimal data correlating the Pediatric Crohn's Disease Activity Index (PCDAI) versions (PCDAI, weighted Pediatric Crohn's Disease Activity Index [wPCDAI], abbreviated Pediatric Crohn's Disease Activity Index [abbrPCDAI], and the short Pediatric Crohn's Disease Activity Index [shPCDAI]) with mucosal inflammation.
METHODS: We aimed to compare the 4 PCDAI versions head to head with endoscopic degree of inflammation as measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) and to explore cut-off values that are associated with mucosal healing. We used the prospectively collected data from the ImageKids study on 100 children with CD undergoing colonoscopy and from the Growth Relapse and Outcomes with Therapy study (n = 222), in which 145 children had calprotectin data at week 12 after diagnosis.
RESULTS: All 4 PCDAI versions had fair correlation with the SES-CD (r = 0.42-0.45, all P < 0.001) and CRP (r = 0.32-0.45, all P < 0.01); the wPCDAI and PCDAI were superior to the shorter versions when comparing the blood tests. All versions had poor correlation with calprotectin, and only the wPCDAI reached significance (r = 0.26, P = 0.002 vs r = 0.15, P = 0.07 for PCDAI; r = 0.08, P = 0.37 for shPCDAI; r = 0.06, P = 0.5 for abbrPCDAI). The best cut-off to identify endoscopic mucosal healing was <12.5 points for the wPCDAI (sensitivity 58% and specificity 84%) and <10 for PCDAI (sensitivity 63% and specificity 77%).
CONCLUSIONS: The more feasible wPCDAI and the PCDAI had comparable correlation with measures of endoscopic inflammation. These were slightly superior to the other 2 shorter versions, but still none of the PCDAI versions can give a valid assessment of mucosal healing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27050050     DOI: 10.1097/MPG.0000000000001227

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  20 in total

1.  A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy.

Authors:  Phillip Minar; Kimberly Jackson; Yi-Ting Tsai; Michael J Rosen; Michael Northcutt; Marat Khodoun; Fred D Finkelman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

Review 2.  Inflammatory Bowel Disease in Childhood and Adolescence.

Authors:  Jan Däbritz; Patrick Gerner; Axel Enninger; Martin Claßen; Michael Radke
Journal:  Dtsch Arztebl Int       Date:  2017-05-12       Impact factor: 5.594

3.  Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.

Authors:  Subra Kugathasan; Lee A Denson; Thomas D Walters; Mi-Ok Kim; Urko M Marigorta; Melanie Schirmer; Kajari Mondal; Chunyan Liu; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Scott Snapper; Shervin Rabizadeh; Joel R Rosh; Jason M Shapiro; Stephen Guthery; David R Mack; Richard Kellermayer; Michael D Kappelman; Steven Steiner; Dedrick E Moulton; David Keljo; Stanley Cohen; Maria Oliva-Hemker; Melvin B Heyman; Anthony R Otley; Susan S Baker; Jonathan S Evans; Barbara S Kirschner; Ashish S Patel; David Ziring; Bruce C Trapnell; Francisco A Sylvester; Michael C Stephens; Robert N Baldassano; James F Markowitz; Judy Cho; Ramnik J Xavier; Curtis Huttenhower; Bruce J Aronow; Greg Gibson; Jeffrey S Hyams; Marla C Dubinsky
Journal:  Lancet       Date:  2017-03-02       Impact factor: 79.321

4.  The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients.

Authors:  Wenjuan Tang; Wenhui Hu; Peng Shi; Ziqing Ye; Jie Wu; Ye Zhang; Yuhuan Wang; Ying Huang
Journal:  Front Pediatr       Date:  2022-05-18       Impact factor: 3.569

5.  Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study.

Authors:  Darja Urlep; Evgen Benedik; Jernej Brecelj; Rok Orel
Journal:  Eur J Pediatr       Date:  2019-11-28       Impact factor: 3.183

6.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

7.  Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients.

Authors:  Kathryn Clarkston; Yi-Ting Tsai; Kimberly Jackson; Michael J Rosen; Lee A Denson; Phillip Minar
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-07       Impact factor: 2.839

8.  Poor Concordance Between Clinical Activity and Endoscopic Severity in Pediatric Crohn's Disease: Before and After Induction Therapy.

Authors:  Yu Yu; Hong Zhao; Youyou Luo; Jingan Lou; Jie Chen; Youhong Fang
Journal:  Dig Dis Sci       Date:  2021-04-05       Impact factor: 3.199

9.  Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.

Authors:  Ruben J Colman; Yi-Ting Tsai; Kimberly Jackson; Brendan M Boyle; Joshua D Noe; Jeffrey S Hyams; Geert R A M D'Haens; Johan van Limbergen; Michael J Rosen; Lee A Denson; Phillip Minar
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

10.  Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.

Authors:  Claudia Loganes; Alessia Pin; Samuele Naviglio; Martina Girardelli; Anna Monica Bianco; Stefano Martelossi; Alberto Tommasini; Elisa Piscianz
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.